RAB44

Summary

RAB44 (RAB44, member RAS oncogene family, HGNC:21068) is a protein-coding gene on chromosome 6p21.2, encoding Ras-related protein Rab-44 (Q7Z6P3). The small GTPases Rab are key regulators of intracellular membrane trafficking, from the formation of transport vesicles to their fusion with membranes.

Predicted to enable GTP binding activity and GTPase activity. Predicted to be involved in vesicle-mediated transport. Predicted to act upstream of or within histamine secretion by mast cell and histamine secretion mediated by IgE immunoglobulin. Predicted to be located in azurophil granule membrane; plasma membrane; and specific granule membrane.

Source: NCBI Gene 401258 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 9 total
• MANE Select transcript: NM_001257357

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:21068
Approved symbol	RAB44
Name	RAB44, member RAS oncogene family
Location	6p21.2
Locus type	gene with protein product
Status	Approved
Aliases	dJ431A14.3
Ensembl gene	ENSG00000255587
Ensembl biotype	protein_coding
Entrez	401258

Gene structure

Transcript identifiers

Ensembl transcripts: 2 — 2 protein_coding

ENST00000612677, ENST00000957683

RefSeq mRNA: 1 — MANE Select: NM_001257357 NM_001257357

CCDS: CCDS75442

Canonical transcript exons

ENST00000612677 — 14 exons

Exon	Start	End
ENSE00000749010	36727577	36727691
ENSE00001159145	36725862	36725943
ENSE00001192733	36721151	36722733
ENSE00002224510	36728700	36728801
ENSE00003279854	36730673	36730749
ENSE00003432941	36720363	36720550
ENSE00003705387	36715479	36715653
ENSE00003708428	36717273	36717419
ENSE00003710671	36718493	36718588
ENSE00003710885	36718028	36718118
ENSE00003718758	36704224	36704442
ENSE00003726304	36732003	36733184
ENSE00003734569	36713828	36713939
ENSE00003743820	36697826	36697915

Expression profiles

Bgee: expression breadth broad, 75 present calls, max score 85.95.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 2.5414 / max 364.7018, expressed in 149 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
67560	2.2942	146
67561	0.2472	64

Top tissues by expression

117 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
bone marrow	UBERON:0002371	85.95	gold quality
monocyte	CL:0000576	80.37	gold quality
leukocyte	CL:0000738	79.95	gold quality
bone marrow cell	CL:0002092	79.44	gold quality
granulocyte	CL:0000094	78.79	gold quality
blood	UBERON:0000178	74.53	gold quality
gall bladder	UBERON:0002110	58.76	gold quality
upper lobe of left lung	UBERON:0008952	58.30	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	57.49	gold quality
urinary bladder	UBERON:0001255	57.44	gold quality
lower esophagus muscularis layer	UBERON:0035833	57.40	gold quality
lower esophagus	UBERON:0013473	57.35	gold quality
duodenum	UBERON:0002114	57.33	gold quality
vermiform appendix	UBERON:0001154	56.53	gold quality
right lung	UBERON:0002167	56.50	gold quality
lower esophagus mucosa	UBERON:0035834	55.74	gold quality
subcutaneous adipose tissue	UBERON:0002190	55.69	gold quality
spleen	UBERON:0002106	55.47	gold quality
skin of leg	UBERON:0001511	55.39	gold quality
mucosa of stomach	UBERON:0001199	55.28	gold quality
esophagus	UBERON:0001043	55.24	gold quality
smooth muscle tissue	UBERON:0001135	55.20	gold quality
lung	UBERON:0002048	54.76	gold quality
zone of skin	UBERON:0000014	53.88	gold quality
colonic epithelium	UBERON:0000397	53.56	gold quality
esophagus mucosa	UBERON:0002469	53.38	gold quality
muscle tissue	UBERON:0002385	53.11	gold quality
right uterine tube	UBERON:0001302	52.79	gold quality
adipose tissue	UBERON:0001013	52.74	gold quality
body of stomach	UBERON:0001161	52.74	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-MTAB-6075	yes	55.95
E-MTAB-9067	yes	14.11
E-ANND-3	yes	4.40

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

40 targeting RAB44, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6851-5P	100.00	65.63	1294
HSA-MIR-3689D	100.00	66.14	1181
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-4283	100.00	66.42	2097
HSA-MIR-511-3P	99.99	68.85	1467
HSA-MIR-6844	99.82	70.69	2423
HSA-MIR-4694-3P	99.79	69.53	2640
HSA-MIR-1299	99.77	71.24	2389
HSA-MIR-92A-2-5P	99.75	67.01	2164
HSA-MIR-875-3P	99.63	69.47	2548
HSA-MIR-12131	99.48	68.72	1673
HSA-MIR-653-5P	99.46	67.35	1300
HSA-MIR-4762-3P	99.43	69.72	2363
HSA-MIR-5695	99.41	67.48	1047
HSA-MIR-519D-5P	99.41	69.30	2057
HSA-MIR-520A-5P	99.35	66.72	1632
HSA-MIR-525-5P	99.35	66.85	1615
HSA-MIR-542-3P	99.34	67.58	1270
HSA-MIR-3692-5P	99.29	67.04	1421
HSA-MIR-5589-3P	99.29	68.30	1443
HSA-MIR-6071	99.16	67.77	1780
HSA-MIR-7854-3P	99.08	66.26	1117
HSA-MIR-8070	99.07	69.30	1303
HSA-MIR-1257	98.97	68.02	1133
HSA-MIR-6770-5P	98.97	66.76	1853
HSA-MIR-6074	98.89	69.64	2187
HSA-MIR-6769B-5P	98.73	64.91	1092
HSA-MIR-6840-3P	98.68	65.95	1923
HSA-MIR-6771-3P	98.20	66.53	971
HSA-MIR-6867-3P	98.12	66.07	1305

Literature-anchored findings (GeneRIF, showing 1)

• Rab44 isoforms similarly promote lysosomal exocytosis, but exhibit differential localization in mast cells. (PMID:33641252)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	rab44	ENSDARG00000028389
mus_musculus	Rab44	ENSMUSG00000064147
rattus_norvegicus	Rab44	ENSRNOG00000001869

Paralogs (68): RAB27B (ENSG00000041353), RAB27A (ENSG00000069974), RAB7A (ENSG00000075785), RABL2B (ENSG00000079974), RAB21 (ENSG00000080371), RAB10 (ENSG00000084733), RAB18 (ENSG00000099246), RAB36 (ENSG00000100228), IFT27 (ENSG00000100360), RAB40AL (ENSG00000102128), RAB11A (ENSG00000103769), RAB2A (ENSG00000104388), RAB3D (ENSG00000105514), RAB3A (ENSG00000105649), RAB5C (ENSG00000108774), RAB34 (ENSG00000109113), RAB5B (ENSG00000111540), RAB35 (ENSG00000111737), RAB23 (ENSG00000112210), DNAJC27 (ENSG00000115137), RAB29 (ENSG00000117280), RAB32 (ENSG00000118508), RAB14 (ENSG00000119396), RAB9B (ENSG00000123570), RAB9A (ENSG00000123595), RAB38 (ENSG00000123892), RAB22A (ENSG00000124209), RAB17 (ENSG00000124839), RAB2B (ENSG00000129472), RAB25 (ENSG00000132698), RAB33A (ENSG00000134594), RAB30 (ENSG00000137502), RAB1A (ENSG00000138069), RAB20 (ENSG00000139832), RAB15 (ENSG00000139998), RAB40B (ENSG00000141542), RAB13 (ENSG00000143545), RABL2A (ENSG00000144134), RAB5A (ENSG00000144566), RAB19 (ENSG00000146955)

Protein

Protein identifiers

Ras-related protein Rab-44 — Q7Z6P3 (reviewed: Q7Z6P3)

All UniProt accessions (1): Q7Z6P3

UniProt curated annotations — full annotation on UniProt →

Function. The small GTPases Rab are key regulators of intracellular membrane trafficking, from the formation of transport vesicles to their fusion with membranes. Rabs cycle between an inactive GDP-bound form and an active GTP-bound form that is able to recruit to membranes different sets of downstream effectors directly responsible for vesicle formation, movement, tethering and fusion. Promotes mast cell degranulation upon IgE Fc receptor (FcERI)-mediated activation.

Subunit / interactions. Interacts with VAMP8; VAMP8 may act as RAB44 effector in mast cell degranulation.

Subcellular location. Cell membrane. Lysosome membrane.

Activity regulation. Regulated by guanine nucleotide exchange factors (GEFs) which promote the exchange of bound GDP for free GTP. Regulated by GTPase activating proteins (GAPs) which increase the GTP hydrolysis activity. Inhibited by GDP dissociation inhibitors (GDIs).

Domain organisation. Switch I, switch II and the interswitch regions are characteristic of Rab GTPases and mediate the interactions with Rab downstream effectors. The switch regions undergo conformational changes upon nucleotide binding which drive interaction with specific sets of effector proteins, with most effectors only binding to GTP-bound Rab.

Similarity. Belongs to the small GTPase superfamily. Rab family.

RefSeq proteins (1): NP_001244286* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001806	Small_GTPase	Family
IPR002048	EF_hand_dom	Domain
IPR005225	Small_GTP-bd	Domain
IPR011992	EF-hand-dom_pair	Homologous_superfamily
IPR027417	P-loop_NTPase	Homologous_superfamily
IPR050227	Rab	Family

Pfam: PF00071

Catalyzed reactions (Rhea), 1 shown:

• GTP + H2O = GDP + phosphate + H(+) (RHEA:19669)

UniProt features (37 total): binding site 13, compositionally biased region 10, region of interest 7, lipid moiety-binding region 2, mutagenesis site 2, chain 1, domain 1, coiled-coil region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q7Z6P3-F1	58.25	0.21

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (13): 842; 845; 846; 847; 847; 865; 865; 888; 891; 946; 947; 949 …

Post-translational modifications (2): 1019, 1020

Mutagenesis-validated functional residues (2):

Position	Phenotype
847	constitutively inactive (gdp-bound) mutant. increased b-hexosaminidase secretion upon fceri-mediated activation, similar
892	constitutively active (gtp-bound) mutant. no change in beta-hexosaminidase secretion upon fceri-mediated activation, com

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-6798695	Neutrophil degranulation
R-HSA-8873719	RAB geranylgeranylation

MSigDB gene sets: 82 (showing top): GOBP_RESPONSE_TO_NITROGEN_COMPOUND, REACTOME_INNATE_IMMUNE_SYSTEM, GOBP_INFLAMMATORY_RESPONSE, GOCC_VACUOLAR_MEMBRANE, GOCC_SECRETORY_GRANULE, IVANOVA_HEMATOPOIESIS_LATE_PROGENITOR, GOBP_REGULATION_OF_HORMONE_LEVELS, GOBP_HORMONE_TRANSPORT, GOBP_VESICLE_MEDIATED_TRANSPORT, GOBP_LEUKOCYTE_MEDIATED_IMMUNITY, GOBP_CELL_CELL_SIGNALING, GOBP_CELL_ACTIVATION_INVOLVED_IN_IMMUNE_RESPONSE, GOBP_MAST_CELL_ACTIVATION, GOBP_EXOCYTOSIS, GOBP_MYELOID_LEUKOCYTE_ACTIVATION

GO Biological Process (4): histamine secretion by mast cell (GO:0002553), vesicle-mediated transport (GO:0016192), mast cell degranulation (GO:0043303), histamine secretion mediated by IgE immunoglobulin (GO:0097279)

GO Molecular Function (6): GTPase activity (GO:0003924), G protein activity (GO:0003925), calcium ion binding (GO:0005509), GTP binding (GO:0005525), nucleotide binding (GO:0000166), protein binding (GO:0005515)

GO Cellular Component (8): lysosomal membrane (GO:0005765), endoplasmic reticulum membrane (GO:0005789), plasma membrane (GO:0005886), early endosome membrane (GO:0031901), azurophil granule membrane (GO:0035577), specific granule membrane (GO:0035579), membrane (GO:0016020), specific granule (GO:0042581)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Innate Immune System	1
Post-translational protein modification	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
secretory granule membrane	2
histamine secretion involved in inflammatory response	1
mast cell degranulation	1
establishment of localization in cell	1
exocytic process	1
transport	1
cellular process	1
mast cell activation involved in immune response	1
mast cell mediated immunity	1
lysosome localization	1
leukocyte degranulation	1
establishment of organelle localization	1
histamine secretion mediated by immunoglobulin	1
ribonucleoside triphosphate phosphatase activity	1
GTPase activity	1
molecular function regulator activity	1
metal ion binding	1
guanyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
binding	1
lysosome	1
lytic vacuole membrane	1
organelle membrane	1
nuclear outer membrane-endoplasmic reticulum membrane network	1
endoplasmic reticulum subcompartment	1
membrane	1
cell periphery	1
early endosome	1
endosome membrane	1
lysosomal membrane	1
azurophil granule	1
specific granule	1
cellular anatomical structure	1
secretory granule	1

Protein interactions and networks

STRING

952 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
RAB44	VAMP8	Q9BV40	535
RAB44	PTX4	Q96A99	485
RAB44	SYTL2	Q9HCH5	451
RAB44	FOXRED2	Q8IWF2	381
RAB44	CCDC13	Q8IYE1	375
RAB44	NFATC1	O95644	372
RAB44	OR1E2	P47887	368
RAB44	VPS52	Q8N1B4	362
RAB44	TREML2	Q5T2D2	357
RAB44	CCDC148	Q8NFR7	356
RAB44	RASEF	Q8IZ41	352
RAB44	MTCH1	Q9NZJ7	342
RAB44	RGL2	O15211	342
RAB44	RILPL2	Q969X0	340
RAB44	MRPL50	Q8N5N7	332

IntAct

2 interactions, top by confidence:

A	B	Type	Score
CRY1	IGKV2D-30	psi-mi:“MI:0914”(association)	0.350

ESM2 similar proteins: A1YGK1, A2T7E6, A4D1S0, A9YTQ3, B1WBS3, I7HJS4, O43593, O43918, O60304, O75593, O95201, P0C6A0, P0C7X2, P97609, Q2MHN3, Q3B7M4, Q3SY56, Q3U133, Q58DK7, Q5JPB2, Q5SXI5, Q5T619, Q61645, Q6KAU7, Q6NUN9, Q6ZMS7, Q76NI1, Q7Z6P3, Q8BZ34, Q8BZW2, Q8CGW9, Q8IWN7, Q8IXT2, Q8IZ20, Q8NBB4, Q8NDX1, Q8NHY3, Q91X45, Q96PX9, Q99558

Diamond homologs: A0JP75, A1A600, B0BNK9, Q3UP38, Q7Z6P3, Q80ZJ8, Q8CB87, Q8N4Y2, Q9BSW2, Q619T5, A4IHM6, F1PTE3, F4KFD8, O13876, O23657, O49841, P35286, P51153, P51157, P51158, P51159, Q14964, Q17QU4, Q18969, Q32LJ6, Q3SWY9, Q58DS5, Q5HYI8, Q5KTJ6, Q5RFI2, Q5UQ27, Q5ZKR4, Q6GPS4, Q6TNS7, Q7T3A4, Q8BHC1, Q8BHD0, Q8N4Z0, Q948K8, Q96DA2

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

9 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	3
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2686 predictions. Top by Δscore:

Variant	Effect	Δscore
6:36704440:GCG:G	donor_gain	1.0000
6:36713935:ACTCA:A	donor_gain	1.0000
6:36713937:TCAGT:T	donor_loss	1.0000
6:36713938:CAG:C	donor_loss	1.0000
6:36713939:AGTA:A	donor_loss	1.0000
6:36713940:GTAT:G	donor_gain	1.0000
6:36713941:T:G	donor_loss	1.0000
6:36715477:AGA:A	acceptor_loss	1.0000
6:36715478:GA:G	acceptor_gain	1.0000
6:36715478:GAAA:G	acceptor_gain	1.0000
6:36715601:G:GT	donor_gain	1.0000
6:36715651:CAAGT:C	donor_loss	1.0000
6:36715652:AA:A	donor_gain	1.0000
6:36715652:AAG:A	donor_loss	1.0000
6:36715653:AGTA:A	donor_loss	1.0000
6:36715654:G:GG	donor_gain	1.0000
6:36715654:GT:G	donor_loss	1.0000
6:36715655:T:A	donor_loss	1.0000
6:36717270:CA:C	acceptor_loss	1.0000
6:36717271:A:AG	acceptor_gain	1.0000
6:36717272:G:GT	acceptor_gain	1.0000
6:36717272:GGC:G	acceptor_gain	1.0000
6:36717272:GGCA:G	acceptor_gain	1.0000
6:36717394:G:GT	donor_gain	1.0000
6:36717415:AGGAA:A	donor_gain	1.0000
6:36717416:GGAA:G	donor_gain	1.0000
6:36717416:GGAAG:G	donor_gain	1.0000
6:36717417:G:T	donor_gain	1.0000
6:36717417:GAA:G	donor_gain	1.0000
6:36717417:GAAG:G	donor_gain	1.0000

AlphaMissense

6591 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
6:36722671:A:T	K846I	0.999
6:36725925:A:C	D888A	0.997
6:36725925:A:T	D888V	0.997
6:36722652:G:A	G840R	0.996
6:36722652:G:C	G840R	0.996
6:36722653:G:A	G840E	0.996
6:36722653:G:T	G840V	0.996
6:36722672:A:C	K846N	0.996
6:36722672:A:T	K846N	0.996
6:36704423:T:A	V63D	0.995
6:36725924:G:C	D888H	0.995
6:36727627:T:C	L911P	0.995
6:36727632:T:G	Y913D	0.995
6:36722671:A:C	K846T	0.994
6:36725913:T:C	L884P	0.994
6:36727636:A:T	D914V	0.994
6:36722641:T:A	V836D	0.992
6:36722668:G:A	G845D	0.992
6:36722668:G:T	G845V	0.992
6:36727653:A:C	S920R	0.992
6:36727655:C:A	S920R	0.992
6:36727655:C:G	S920R	0.992
6:36722670:A:C	K846Q	0.991
6:36722680:T:C	F849S	0.991
6:36725925:A:G	D888G	0.991
6:36725924:G:T	D888Y	0.990
6:36727674:T:A	W927R	0.990
6:36727674:T:C	W927R	0.990
6:36728744:G:C	K947N	0.990
6:36728744:G:T	K947N	0.990

dbSNP variants (sampled 300 via entrez): RS1000041053 (6:36699512 G>A,C), RS1000098835 (6:36705086 A>C,T), RS1000158524 (6:36719246 G>A), RS1000212932 (6:36704865 A>G), RS1000285436 (6:36711208 A>G), RS1000379554 (6:36701688 C>A), RS1000384016 (6:36732708 C>G), RS1000408445 (6:36708093 T>A), RS1000459835 (6:36720282 G>A), RS1000522823 (6:36703331 T>C), RS1000559365 (6:36699296 C>A,T), RS1000743433 (6:36715504 C>A,T), RS1000798981 (6:36710982 C>T), RS1000801189 (6:36709867 G>A), RS1000856940 (6:36732646 G>A)

Disease associations

OMIM: gene `` | disease phenotypes: MIM:607174

GenCC curated gene-disease

Mondo (1): familial meningioma (MONDO:0011789)

Orphanet (1): Familial multiple meningioma (Orphanet:263662)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST009187_2	Lateral occipital cortex volume	3.000000e-06
GCST010041_1	Cortical thickness	3.000000e-07

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004840	cortical thickness

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
C537443	Meningioma, familial (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

12 total (human), top 12 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	increases expression	2
aristolochic acid I	increases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	affects cotreatment, increases methylation	1
di-n-butylphosphoric acid	affects expression	1
theaflavin-3,3’-digallate	affects expression	1
Resveratrol	affects cotreatment, decreases expression	1
Fulvestrant	affects cotreatment, increases methylation	1
Atrazine	increases expression	1
Cisplatin	decreases expression	1
Plant Extracts	affects cotreatment, decreases expression	1
Okadaic Acid	increases expression	1

Clinical trials (associated diseases)

127 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT04081701	PHASE4	RECRUITING	68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.
NCT04386642	PHASE4	UNKNOWN	Tranexamic Acid Reduce Blood Loss in Meningioma Resection
NCT06377371	PHASE4	RECRUITING	Feasibility of Intraoperative Tracing of Meningioma Using [Cu64]DOTATATE
NCT00517959	PHASE3	UNKNOWN	SCRT Versus Conventional RT in Children and Young Adults With Low Grade and Benign Brain Tumors
NCT01655927	PHASE3	UNKNOWN	Efficacy of Tranexamic Acid in Brain Tumor Resections
NCT03015701	PHASE3	COMPLETED	S9005 Mifepristone in Meningioma
NCT03558516	PHASE3	COMPLETED	Magnesium and Intraoperative Blood Loss in Meningioma Surgery
NCT04305470	PHASE3	COMPLETED	Gleolan for Visualization of Newly Diagnosed or Recurrent Meningioma
NCT00003483	PHASE2	TERMINATED	Antineoplaston Therapy in Treating Patients With Meningioma
NCT00589784	PHASE2	COMPLETED	Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma
NCT00706810	PHASE2	COMPLETED	Combination of Hydroxyurea and Verapamil for Refractory Meningiomas
NCT00859040	PHASE2	COMPLETED	Monthly SOM230C for Recurrent or Progressive Meningioma
NCT01967823	PHASE2	COMPLETED	T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
NCT02523014	PHASE2	RECRUITING	Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
NCT02648997	PHASE2	ACTIVE_NOT_RECRUITING	An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma
NCT02831257	PHASE2	COMPLETED	AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas
NCT02847559	PHASE2	RECRUITING	Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
NCT03013387	PHASE2	WITHDRAWN	Dosimetry Guided PRRT With 90Y-DOTATOC
NCT03071874	PHASE2	UNKNOWN	Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas
NCT03095248	PHASE2	TERMINATED	Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors
NCT03273712	PHASE2	COMPLETED	Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)
NCT03971461	PHASE2	ACTIVE_NOT_RECRUITING	Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma
NCT04082520	PHASE2	RECRUITING	Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
NCT04298541	PHASE2	NOT_YET_RECRUITING	Direct Comparison of Ga-68-DOTATATE and Ga-68-DOTATOC
NCT04374305	PHASE2	RECRUITING	Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
NCT04659811	PHASE2	ACTIVE_NOT_RECRUITING	Stereotactic Radiosurgery and Immunotherapy (Pembrolizumab) for the Treatment of Recurrent Meningioma
NCT05425004	PHASE2	RECRUITING	Cabozantinib for Patients With Recurrent or Progressive Meningioma
NCT05940493	PHASE2	RECRUITING	Abemaciclib in Newly Diagnosed Meningioma Patients
NCT06012929	PHASE2	WITHDRAWN	A Study of ONC201 for Refractory Meningioma
NCT06126588	PHASE2	RECRUITING	Combination of Everolimus and 177Lu-DOTATATE in the Treatment of Grades 2 and 3 Refractory Meningioma: a Phase IIb Clinical Trial
NCT06132685	PHASE2	RECRUITING	Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial
NCT06322342	PHASE2	COMPLETED	Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
NCT06326190	PHASE2	RECRUITING	177Lu-DOTATATE for Recurrent Meningioma
NCT06439420	PHASE2	COMPLETED	CBT-I in Primary Brain Tumor Patients: Phase IIc Randomized Feasibility Pilot Trial
NCT06684795	PHASE2	RECRUITING	FG001 in Subjects with Meningiomas or Presumed Low-Grade Gliomas Scheduled for Neurosurgery
NCT06710249	PHASE2	RECRUITING	Impact of Salovum® and SPC® Flakes on Brain Tumor Induced Edema
NCT06804655	PHASE2	NOT_YET_RECRUITING	Pharmacoscopy for Patients With Refractory Primary Brain Tumors
NCT07428616	PHASE2	RECRUITING	A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
NCT07533942	PHASE2	NOT_YET_RECRUITING	A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma
NCT03267836	PHASE1	TERMINATED	Neoadjuvant Avelumab and Hypofractionated Proton Radiation Therapy Followed by Surgery for Recurrent Radiation-refractory Meningioma